Nocturia think tank: Focus on nocturnal polyuria: ICI-RS 2011

Neurourology and Urodynamics

Volumn 31, Issue 3, 2012, Pages 330-339

  Weiss, Jeffrey P ^a   Ruud Bosch, J L H ^b   Drake, Marcus ^c   Dmochowski, Roger R ^d   Hashim, Hashim ^c   Hijaz, Adonis ^e   Johnson, Theodore M ^f   Juul, Kristian ^g   Nãrgaard, Jens Peter ^g   Norton, Peggy ^h   Robinson, Dudley ⁱ   Tikkinen, Kari A O ^j,k   Van Kerrebroeck, Philip E V ^l   Wein, Alan J ^m  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c BRISTOL UROLOGICAL INSTITUTE   (United Kingdom)

^d VANDERBILT UNIVERSITY   (United States)

^e UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^f EMORY UNIVERSITY   (United States)

^g Ferring   (United States)

^h UNIVERSITY OF UTAH   (United States)

ⁱ KING'S COLLEGE LONDON   (United Kingdom)

^j UNIVERSITY OF HELSINKI   (Finland)

^k MCMASTER UNIVERSITY   (Canada)

^l MAASTRICHT UNIVERSITY   (Netherlands)

^m UNIVERSITY OF PENNSYLVANIA   (United States)

more..

Author keywords

nocturia; nocturnal polyuria; nocturnal urinary frequency

Indexed keywords

ACETAZOLAMIDE; ALCOHOL; AMPHOTERICIN B; BUTORPHANOL; CALCIUM CHANNEL BLOCKING AGENT; CARBONATE DEHYDRATASE INHIBITOR; CISPLATIN; CLOZAPINE; CONIVAPTAN; DEMECLOCYCLINE; DESMOPRESSIN; FLUPHENAZINE; FOSCARNET; GLUCOCORTICOID; HALOPERIDOL; IFOSFAMIDE; LITHIUM; METHAZOLAMIDE; METHOXYFLURANE; MORPHINE; OXILORPHAN; PHENYTOIN; PROMETHAZINE; RETINOL; SOLIFENACIN; THIAZIDE DIURETIC AGENT; TOLTERODINE; TOLVAPTAN; UNINDEXED DRUG; VITAMIN D;

AGE; ALGORITHM; BLADDER CAPACITY; BRADYCARDIA; CARBON DIOXIDE BLOOD LEVEL; CIRCADIAN RHYTHM; COGNITIVE THERAPY; COMORBIDITY; COMPRESSION THERAPY; DRUG DOSE TITRATION; DRUG INDICATION; DRUG WITHDRAWAL; EVENING DOSAGE; FLUID INTAKE; FOLLOW UP; HUMAN; HYPONATREMIA; LUNG VASOCONSTRICTION; MEDICAL HISTORY; NOCTURIA; NOCTURNAL POLYURIA; OVERACTIVE BLADDER; OXYGEN SUPPLY; PHARMACEUTICAL CARE; PHENOTYPE; PHYSICAL EXAMINATION; POLYDIPSIA; POLYURIA; PREVALENCE; QUALITY OF LIFE; REVIEW; SEX DIFFERENCE; SLEEP APNEA SYNDROME; SLEEP QUALITY; SLEEP WALKING; TREATMENT DURATION; TREATMENT RESPONSE; URINARY FREQUENCY; URINARY TRACT SURGERY; URINE VOLUME;

AGE FACTORS; CIRCADIAN RHYTHM; DIAGNOSTIC TECHNIQUES, UROLOGICAL; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MALE; NOCTURIA; POLYURIA; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS; SEX FACTORS; URINARY BLADDER; URODYNAMICS;

EID: 84859111127     PISSN: 07332467     EISSN: 15206777     Source Type: Journal    
DOI: 10.1002/nau.22219     Document Type: Review

References (101)

1. Kirkland JL, Lye M, Levy DW, et al. Patterns of urine flow and electrolyte excretion in healthy elderly people. Br Med J 1983; 287: 1665.
2. van Kerrebroeck P, Abrams P, Chaikin D, et al. The standardisation of terminology in nocturia: Report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21: 179-83.
3. Matthiesen TB, Rittig S, Norgaard JP, et al. Nocturnal polyuria and natriuresis in male patients with nocturia and lower urinary tract symptoms. J Urol 1996; 156: 1292.
4. Blanker MH, Bernsen RMD, Bosch JLHR, et al. Relation between nocturnal voiding frequency and nocturnal urine production in older men. Urology 2002; 60: 612-6.
5. Jensen D,. Pharmacological studies of the uninhibited neurogenic bladder. III. The influence of adrenergic excitatory and inhibitory drugs on the cystometrogram of neurological patients with normal and uninhibited neurogenic bladder. Acta Neurol Scand 1981; 64: 401-26.
6. Hall SA, Chiu GR, Kaufman DW, et al. Commonly used antihypertensives and lower urinary tract symptoms: Results from the Boston Area Community Health Survey. BJUI 2011. DOI:10.1111/j.1464-410X.2011.10593.x (Epub ahead of print).
7. Weiss JP, Blaivas JG, Jones M, et al. Age related pathogenesis of nocturia in patients with overactive bladder. J Urol 2007; 178: 548.
8. Tikkinen KA, Auvinen A, Johnson TM II, et al. A systematic evaluation of factors associated with nocturia-The population-based FINNO study. Am J Epidemiol 2009; 170: 361-8.
9. Adam P,. Evaluation and management of diabetes insipidus. Am Fam Physician 1997; 55: 2146.
10. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function; Report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21: 167-78.
11. Weiss JP, Blaivas JG,. Nocturia. J Urol 2000; 163: 5-12.
12. van Mastrigt R, Eijskoot F,. Analysis of voided urine volumes measured using a small electronic pocket balance. Scand J Urol Nephrol 1996; 30: 257-63.
13. van Doorn B, Blanker M, Bosch R,. The epidemiology of nocturnal polyuria (incidence and prevalence): A longitudinal community based study in men between 50 and 78 years of age. Neurourol Urodyn 2009; 28: 765-6.
14. Yalkut D, Lee LY, Grider J, et al. Mechanism of atrial natriuretic peptide release with increased inspiratory resistance. J Lab Clin Med 1996; 128: 322-8.
15. Ichioka M, Hirata Y, Inase N, et al. Changes of circulating atrial natriuretic peptide and antidiuretic hormone in obstructive sleep apnea syndrome. Respiration 1992; 59: 164-8.
16. Umlauf MG, Chasens ER, Greevy RA, et al. Obstructive sleep apnea, nocturia and polyuria in older adults. Sleep 2004; 27: 139-44.
17. Fitzgerald MP, Mulligan M, Parthasarathy S,. Nocturic frequency is related to severity of obstructive sleep apnea, improves with continuous positive airways treatment. Am J Obstet Gynecol 2006; 194: 1399-403.
18. Margel D, Shochat T, Getzler O, et al. Continuous positive airway pressure reduces nocturia in patients with obstructive sleep apnea. Urology 2006; 67: 974-7.
19. Hashim H, Coyne K, Chapple C, et al. Nocturia: Risk factors and associated comorbid conditions findings from an international cross-sectional study: EpiLUTS (Abstract 884). Eur Urol Suppl 2011; 10: 278.
20. Chen CY, Hsu CC, Pei YC, et al. Nocturia is an independent predictor of severe obstructive sleep apnea in patients with ischemic stroke. J Neurol 2011; 258: 189-94.
21. Romero E, Krakow B, Haynes P, et al. Nocturia and snoring: Predictive symptoms for obstructive sleep apnea. Sleep Breath 2010; 14: 337-43.
22. Kemmer H,. The relationship between sleep apnea and overactive bladder. Curr Urol Rep 2009; 10: 448-50.
23. Lowenstein L, Kenton K, Brubaker L, et al. The relationship between obstructive sleep apnea, nocturia, and daytime overactive bladder syndrome in women. Am J Obstet Gynecol 2008; 198: 598-5.
24. Tandeter H, Gendler S, Dreiher J, et al. Nocturic episodes in patients with benign prostatic enlargement may suggest the presence of obstructive sleep apnea. J Am Board Fam Med 2011; 24: 146-51.
25. Hasan A, Uzma N, Swamy TL, et al. Correlation of clinical profiles with obstructive sleep apnea and metabolic syndrome. Sleep Breath 2012; 16: 111-6.
26. Gulur DM, Mevcha AM, Drake MJ,. Nocturia as a manifestation of systemic disease. BJU Int 2011; 107: 702-13.
27. Tikkinen KA, Johnson TM II, Tammela TL, et al. Nocturia frequency, bother and quality of life-How often is too often? A population-based study in Finland. Eur Urol 2010; 57: 488-98.
28. Osoba D,. Guidelines for measuring quality of life in clinical trials. In: Staquet-Hays-Fayers: Quality of Life Assessment in Clinical trials. Oxford, UK: Oxford University Press; 1998.
29. Abraham L, Hareendran A, Mills IW, et al. Development and validation of a quality-of-life measure for men with nocturia. Urology 2004; 63: 481-6.
30. McKown S, Abraham L, Coyne K, et al. Linguistic validation of the N-QOL (ICIQ), OAB-q (ICIQ), PPBC, OAB-S and ICIQ-MLUTS sex questionnaires in 16 languages. Int J Clin Pract 2010; 64: 1643-52.
31. Buysse DJ, Reynolds CF III, Monk TH, et al. The Pittsburgh Sleep Quality Index: A new instrument for psychiatric practice and research. Psychiatry Res 1989; 28: 193-213.
32. Yu HJ, Chen FY, Huang PC, et al. Impact of nocturia on symptom-specific quality of life among community-dwelling adults aged 40 years and older. Urology 2006; 67: 713-8.
33. Bing MH, Moller LA, Jennum P, et al. Validity and reliability of a questionnaire for evaluating nocturia, nocturnal enuresis and sleep-interruptions in an elderly population. Eur Urol 2006; 49: 710-9.
34. Coyne KS, Margolis MK, Hsieh R, et al. Validation of the urinary sensation scale (USS). Neurourol Urodyn 2011; 30: 360-5.
35. Van Diest R, Appels WP,. Sleep physiological characteristics of exhausted men. Psychosom Med 1994; 56: 28-35.
36. Hays RD, Sherbourne CD, Mazel RM, et al. The RAND 36-item health survey 1.0. Health Economics 1993; 2: 217-27.
37. van Dijk L, Kooij DG, Schellevis FS, et al. Nocturia: Impact on quality of life in a Dutch adult population. BJU Int 2004; 93: 1001-4.
38. Jackson S, Donovan J, Brookes S, et al. The Bristol Female Lower Urinary Tract Symptoms questionnaire. Development and psychometric testing. Br J Urol 1996; 77: 805-12.
39. Barry M, Fowler FJ, Jr., O'Leary MP, et al. Measuring disease-specific health status in men with benign prostatic hyperplasia. Med Care 1995; 33: AS145-55.
40. Donovan JL, Peters KTJ, Abrams P, et al. Using ICSQoL to measure the impact of lower urinary tract symptoms on quality of life: Evidence from the ICS-'BPH' study. Br J Urol 1997; 80: 712-21.
41. Epstein RS, Deverka P, Chute CG, et al. Validation of a new quality of life questionnaire for benign prostatic hyperplasia. J Clin Epidemiol 1992; 45: 1431-45.
42. Department of Veterans Affairs Cooperative Study of transurethral resection for benign prostatic hyperplasia. A comparison of quality of life with patient reported symptoms and objective findings in men with benign prostatic hyperplasia. J Urol 1993; 150: 1696-700.
43. Girman CJ, Jacobsen SJ, Tsukamoto T, et al. Natural history of prostatism: Impact of urinary symptoms on quality of life in 2115 randomly selected community men. Urology 1994; 44: 825.
44. Shumaker SA, Wyman JF, Uebersax JS, et al. Health-related quality of life measures for women with urinary incontinence: The Incontinence Impact Questionnaire and the Urogenital Distress Inventory. Qual Life Res 1994; 3: 291-306.
45. Kelleher CJ, Cardozo LD, Khullar V, et al. A new questionnaire to assess the quality of life of urinary incontinent women. Br J Obstet Gynaecol 1997; 104: 1374-79.
46. Donovan JL,. Measuring the impact of nocturia on quality of life. BJU Int 1999; 84: 21-5.
47. Sintonen H,. The 15D instrument of health-related quality of life: Properties and applications. Ann Med 2001; 33: 328-36.
48. Chen FY, Dai YT, Liu CK, et al. Perception of nocturia and medical consulting behavior among community-dwelling women. Int Urogynecol J Pelvic Floor Dysfunct 2007; 18: 431-6.
49. Fiske J, Scarpero HM, Xue X, et al. Degree of bother caused by nocturia in women. Neurourol Urodyn 2004; 23: 130-3.
50. Barry MJ, Fowler FJ, O'Leary MP, et al. The American Urological Association Symptom Index for Benign Prostatic Hyperplasia. J Urol 1992; 148: 1549-57.
51. The EuroQol Group. EuroQol-A new facility for the measurement of health related quality of life. Health Policy 1990; 16: 199-208.
52. Brazier JE, Harper R, Jones NMB, et al. Validating the SF-36 health survey questionnaire-New outcome measure for primary care. Br Med J 1992; 305: 160-4.
53. Reilly C, Zbrozek A, Dukes E,. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993; 4: 353-65.
54. Kobelt G, Borgstrom F, Mattiasson A, et al. Productivity, vitality and utility in a group of healthy professionally active individuals with nocturia. BJU Int 2003; 91: 190-5.
55. Lin J, Denker BM,. Azotemia and urinary abnormalities. In:, Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL, Loscalzo J, editors. Harrison's principles of internal medicine, 18th edition. New York: McGraw Hill.
56. Snyder HM, Noland TD, Breyer MD,. cAMP-dependent protein kinase mediates hydrosmotic effect of vasopressin in collecting duct. Am J Physiol 1992; 263: C147-53.
57. Sands JM,. Molecular mechanisms of urea transport, J Membr Biol 2003; 191: 149-63.
58. Reilly RF, Jackson EK,. Regulation of renal function and vascular volume. In:, Brunton LL, Chabner BA, Knollmann BC, editors. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 12th edition. New York: McGraw Hill.
59. Wallia R, Greenberg A, Puschett JB,. Renal hemodynamic and tubular transport effects of nitrendipine. J Lab Clin Med 1985; 105: 498-503.
60. Lehnert H, Schmitz H, Preuss K, et al. Effects of nitrendipine on blood pressure, renin-angiotensin-system and atrial natriuretic peptide in hypertensive type I diabetic patients. Horm Metab Res 1993; 25: 24-8.
61. Rector F, Goyal S, Rosenberg IK, et al. Sepsis: A mechanism for vasodilatation in the kidney, Ann Surg 1973; 178: 222-6.
62. Gilman AG,. Regulation of adenylyl cyclase by G proteins. Adv Second Messenger Phosphoprotein Res 1990; 24: 51-7.
63. Lose G, Mattiasson A, Walter S, et al. Clinical experiences with desmopressin for long-term treatment of nocturia. J Urol 2004; 172: 1021-5.
64. van Kerrebroeck P, Hashim H, Holm-Larsen, et al. Thinking beyond the bladder: Antidiuretic treatment of nocturia. Int J Clin Pract 2010; 64: 807-16.
65. Wang CJ, Lin YN, Huang SW, et al. Low dose oral desmopressin for nocturnal polyuria in patients with benign prostatic hyperplasia: A double-blind, placebo controlled, randomized study. J Urol 2011; 185: 219-23.
66. Kang DI, Kim HM, Oh SY, et al. Short term effect and safety of antidiuretic hormone in the patients with nocturia. Int Neurourol J 2010; 14: 227-31.
67. Lee HW, Choo M, Lee J, et al. Desmopressin is an effective treatment for mixed nocturia with nocturnal polyuria and decreased nocturnal bladder capacity. J Korean Med Sci 2010; 25: 1792-7.
68. Weiss JP, Blaivas JG, Bliwise DL, et al. The evaluation and treatment of nocturia: A consensus statement. BJU Int 2011; 108: 6-21.
69. Van Kerrebroeck PE, Dmochowski R, Fitzgerald MP, et al. Nocturia research: Current status and future perspectives. Neurourol Urodyn 2010; 29: 623-8.
70. Rembratt A, Riis A, Norgaard JP,. Desmopressin treatment in nocturia; an analysis of risk factors for hyponatremia. Neurourol Urodyn 2006; 25: 105-9.
71. Asplund R, Aberg H,. Diurnal variation in the levels of antidiuretic hormone in the elderly. J Int Med 1991; 229: 131-4.
72. Hvistendahl GM, Frokiaer J, Neilsen S, et al. Gender differences in night-time plasma arginine vasopressin and delayed compensatory urine output in the elderly population after desmopressin. J Urol 2007; 178: 2671-6.
73. Stachenfeld NS, Dipietro L, Palter SF, et al. Oestrogen influences osmotic secretion of AVP and body water balance in postmenopausal women. Am J Physiol Regul Integr Comp Physiol 1998; 274: R187-95.
74. Liu J, Sharma N, Zheng W, et al. Sex differences in vasopressin V2 receptor. FASEB J 2008; 22: 1159-24.
75. Migeon B,. X inactivation, female mosaicism and sex differences in renal diseases. J Am Soc Nephrol 2008; 19: 2052-9.
76. Carrel L, Willard HF,. X-inactivation profile reveals extensive variability in X-linked gene expression in females. Nature 2005; 434: 400-4.
77. Lose G, Lalos O, Freeman R, et al. Efficacy of desmopressin (Minirin) in the treatment of nocturia: A double blind placebo controlled study. Am J Obstet Gynaecol 2003; 189: 1106-13.
78. Mattiasson A, Abrams P, van Kerrebroeck P, et al. Efficacy of desmopressin in the treatment of nocturia; a double blind placebo controlled study in men. BJU Int 2002; 89: 855-62.
79. Weiss J, Zinner N, Daneshgari F, et al. Desmopressin orally disintegrating tablet effectively reduces symptoms of nocturia, and prolongs undisturbed sleep in patients with nocturia. Int J Urogynaecol 2010; 21: S285-7.
80. Juul KV, Klein BM, Sandstrom R, et al. Gender differences in antidiuretic response to desmopressin. Am J Physiol Renal Physiol 2011; 300: F1116-22.
81. Smith AL, Wein AJ,. Outcomes of pharmacological management of nocturia with non-antidiuretic agents: Does statistically significant equal clinically significant ? BJU Int 2011; 107: 1550-4.
82. Brubaker L, Fitzgerald MP,. Nocturnal polyuria and nocturia relief in patients treated with solifenacin for overactive bladder symptoms. Int Urogynecol J Pelvic Floor Dysfunct 2007; 18: 737-41.
83. Rackley R, Weiss JP, Rovner ES, et al. Nighttime dosing with tolterodine reduces bladder-related nocturnal micturitions in patients with overactive bladder and nocturia. Urology 2006; 67: 731-6.
84. Zinner N, Gittleman M, Harris R, et al. Trospium chloride improves overactive bladder symptoms: A multicenter phase III trial. J Urol 2004; 171: 2311-5.
85. Rudy D, Cline K, Harris R, et al. Multicenter phase III trial studying trospium chloride in patients with overactive bladder. Urology 2006; 62: 275-80.
86. Nitti V, Dmochowski R, San P, et al. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. J Urol 2007; 178: 2488-94.
87. Chapple C, Van Kerrebroeck P, Tubaro A, et al. Clinical efficacy, safety, and tolerability of once daily fesoterodine in subjects with overactive bladder. Eur Urol 2007; 52: 1204-12.
88. Herschorn S, Swift S, Guan Z, et al. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: A head-to-head placebo-controlled trial. BJU Int 2010; 105: 58-66.
89. Dmochowski RR, Peters KM, Morrow JD, et al. Randomized, double-blind, placebo controlled trial of flexible dose fesoterodine in subjects with overactive bladder. Urology 2010; 75: 62-8.
90. Kaplan SA, Schneider T, Foote JE, et al. Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: A prospective, head-to-head, placebo controlled trial. BJU Int 2010; 107: 1432.
91. Kallas HE, Chintanadilok J, Maruenda J, et al. Treatment of nocturia in the elderly. Drugs Aging 1999; 15: 429-37.
92. Johnson TM II, Sattin RW, Parmelee P, et al. Evaluating potentially modifiable risk factors for prevalent and incident nocturia in older adults. J Am Geriatr Soc 2005; 53: 1011-6.
93. Swithinbank L, Hashim H, Abrams P,. The effect of fluid intake on urinary symptoms in women. J Urol 2005; 174: 187-9.
94. Hashim H, Abrams P,. How should patients with an overactive bladder manipulate their fluid intake ? BJU Int 2008; 102: 62-6.
95. Torimoto K, Hirayama A, Samma S, et al. The relationship between nocturnal polyuria and the distribution of body fluid: Assessment by bioelectric impedance analysis. J Urol 2009; 181: 219-24.
96. Vaughan CP, Endeshaw Y, Nagamia Z, et al. A multicomponent behavioral and drug intervention for nocturia in elderly men: Rationale and pilot results. BJU Int 2009; 104: 69-74.
97. Reynard JM, Cannon A, Yang Q, et al. A novel therapy for nocturnal polyuria: A double-blind randomized trial of frusemide against placebo. Br J Urol 1998; 81: 215-8.
98. Fu FG, Lavery HJ, Wu DL,. Reducing nocturia in the elderly: A randomized placebo-controlled trial of staggered furosemide and desmopressin. Neurourol Urodyn 2011; 30: 312-6.
99. Zimmern P, Litman HJ, Mueller E, et al. Effect of fluid management on fluid intake and urge incontinence in a trial for overactive bladder in women. BJU Int 2010; 105: 1680-5.
100. Johnson TM II, Burgio KL, Goode PS, et al. Effects of behavioral and drug therapy on nocturia in older incontinent women. J Am Geriatr Soc 2005; 53: 846-50.
101. Burgio KL, Goode PS, Johnson TM II, et al. Behavioral versus drug treatment for overactive bladder in men: The male overactive bladder treatment in veterans (MOTIVE) trial. J Am Geriatr Soc 2011; 59: 2209-16.